Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements 2024
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show 2025
Spring on the Road
Spring Wellness 2025
Canada Votes 2025
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
Ontario Votes
LAST CHANCE AUCTION
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Mirum Pharmaceuticals, Inc.
< Previous
1
2
3
4
5
6
Next >
Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
May 07, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025
April 30, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals to Present Data at Upcoming Medical Congresses
April 28, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum’s LIVMARLI Now FDA Approved in Tablet Formulation
April 14, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 10, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
LIVMARLI Now Approved in Japan for ALGS and PFIC
March 27, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 10, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update
February 26, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum’s CTEXLI™ (chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (CTX)
February 24, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call on February 26, 2025
February 19, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 10, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates
January 13, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 10, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 06, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 10, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD’s The Liver Meeting
November 14, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
November 12, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 08, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
November 07, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024
November 04, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting
October 31, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 10, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Volixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis
October 10, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 10, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
August 28, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 09, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
August 07, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 7, 2024
July 31, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum’s LIVMARLI Now Approved for PFIC in Patients 12 Months and Older
July 25, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 10, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.